Search results
William Blair holds market perform rating on Travere stock, cites Filspari risks By Investing.com
Investing.com· 11 hours agoTuesday, Travere Therapeutics (NASDAQ:TVTX) maintained a Market Perform rating by William Blair, led...
Tenax Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($1.72) Per Share (NASDAQ:TENX)
ETF DAILY NEWS· 5 days agoTenax Therapeutics, Inc. (NASDAQ:TENX – Free Report) – Equities researchers at Zacks Small Cap cut their Q2 2024 earnings per share (EPS) estimates for shares of Tenax < ...
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Zacks· 5 days agoBicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple...
This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year
Simply Wall St. via Yahoo Finance· 4 days agoLooking at BriaCell Therapeutics Corp.'s (TSE:BCT ) insider transactions over the last year, we can...
Actuate Files Registration Statement for IPO By Investing.com
Investing.com· 11 hours agoActuate Therapeutics, Inc. (“Actuate”) announced today that it has filed a registration statement...
This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Simply Wall St. via Yahoo Finance· 6 days agoInsiders were net buyers of Neumora Therapeutics, Inc.'s (NASDAQ:NMRA ) stock during the past year....
Where Will Viking Therapeutics Be in 5 Years?
Motley Fool via Yahoo Finance· 3 days agoIf you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is...
Piper Sandler upgrades CytomX Therapeutics stock, cites promising data By Investing.com
Investing.com· 13 hours agoPiper Sandler upgrades CytomX Therapeutics stock, cites promising data
HC Wainwright Comments on Poseida Therapeutics, Inc.’s Q3 2025 Earnings (NASDAQ:PSTX)
ETF DAILY NEWS· 4 days agoPoseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report) – HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Poseida Therapeutics
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 6 days agoWith a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (NASDAQ: CRSP) is...
